Patient presents with signs and symptoms suggestive of a neuroendocrine tumor (NET).  Clinical presentation includes [Specific symptoms e.g., flushing, diarrhea, wheezing, abdominal pain, peptic ulcer disease].  Patient history includes [Pertinent medical history, family history of NETs, relevant risk factors such as Multiple Endocrine Neoplasia type 1 (MEN1)].  Physical examination reveals [Specific findings e.g., palpable abdominal mass, hepatomegaly].  Biochemical markers such as chromogranin A (CgA), 5-HIAA (5-hydroxyindoleacetic acid), and neuron-specific enolase (NSE) were ordered to aid in diagnosis and assess tumor burden.  Imaging studies, including CT scan, MRI, and or octreoscan (somatostatin receptor scintigraphy), are planned or have been performed to localize the primary tumor and assess for metastasis.  Differential diagnoses include carcinoid syndrome, pancreatic endocrine tumor, small cell lung cancer, and other neuroendocrine neoplasms.  Preliminary diagnosis is consistent with neuroendocrine tumor.  Further investigations are underway to determine tumor grade, stage, and primary site.  Treatment plan will be formulated based on these findings and may include surgical resection, somatostatin analogs (e.g., octreotide, lanreotide), targeted therapies (e.g., everolimus, sunitinib), peptide receptor radionuclide therapy (PRRT), and or chemotherapy.  Patient education provided regarding NETs, prognosis, treatment options, and potential side effects.  Follow-up appointments scheduled for ongoing monitoring and management.  ICD-10 code [Appropriate ICD-10 code e.g., C7A.119] is pending further diagnostic confirmation.